Paratek Pharmaceuticals Inc. [NASDAQ: PRTK] jumped around 0.98 points on Thursday, while shares priced at $5.63 at the close of the session, up 21.08%.
Paratek Pharmaceuticals Inc. stock is now 39.70% up from its year-to-date (YTD) trading value. PRTK Stock saw the intraday high of $5.78 and lowest of $4.875 per share. The company’s 52-week high price is 6.41, which means current price is +125.20% above from all time high which was touched on 07/29/20.
Compared to the average trading volume of 530.85K shares, PRTK reached a trading volume of 3504222 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Paratek Pharmaceuticals Inc. [PRTK]?
WBB Securities have made an estimate for Paratek Pharmaceuticals Inc. shares, keeping their opinion on the stock as Speculative Buy, with their previous recommendation back on January 08, 2020. While these analysts kept the previous recommendation, Canaccord Genuity raised their target price to Buy. The new note on the price target was released on January 02, 2019, representing the official price target for Paratek Pharmaceuticals Inc. stock. Previously, the target price had yet another drop from $55 to $22, while H.C. Wainwright kept a Buy rating on PRTK stock.
The Average True Range (ATR) for Paratek Pharmaceuticals Inc. is set at 0.31, with the Price to Sales ratio for PRTK stock in the period of the last 12 months amounting to 8.59.
How has PRTK stock performed recently?
Paratek Pharmaceuticals Inc. [PRTK] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 22.13. With this latest performance, PRTK shares gained by 28.83% in over the last four-week period, additionally plugging by 79.30% over the last 6 months – not to mention a rise of 5.23% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PRTK stock in for the last two-week period is set at 71.50, with the RSI for the last a single of trading hit 77.22, and the three-weeks RSI is set at 66.53 for Paratek Pharmaceuticals Inc. [PRTK]. The present Moving Average for the last 50 days of trading for this stock 4.69, while it was recorded at 4.64 for the last single week of trading, and 4.14 for the last 200 days.
Paratek Pharmaceuticals Inc. [PRTK]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Paratek Pharmaceuticals Inc. [PRTK] shares currently have an operating margin of -698.92 and a Gross Margin at +75.87. Paratek Pharmaceuticals Inc.’s Net Margin is presently recorded at -778.47.
Return on Total Capital for PRTK is now -46.19, given the latest momentum, and Return on Invested Capital for the company is -51.55. Return on Equity for this stock declined to -3,247.76, with Return on Assets sitting at -46.72. Additionally, PRTK Total Debt to Total Capital is recorded at 117.69, with Total Debt to Total Assets ending up at 105.08.
Reflecting on the efficiency of the workforce at the company, Paratek Pharmaceuticals Inc. [PRTK] managed to generate an average of -$1,262,647 per employee. Receivables Turnover for the company is 3.37 with a Total Asset Turnover recorded at a value of 0.06.Paratek Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.00 and a Current Ratio set at 6.50.
Earnings analysis for Paratek Pharmaceuticals Inc. [PRTK]
With the latest financial reports released by the company, Paratek Pharmaceuticals Inc. posted -1/share EPS, while the average EPS was predicted by analysts to be reported at -1.05/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 4.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PRTK.
Insider trade positions for Paratek Pharmaceuticals Inc. [PRTK]
There are presently around $121 million, or 50.80% of PRTK stock, in the hands of institutional investors. The top three institutional holders of PRTK stocks are: BLACKROCK INC. with ownership of 2,761,736, which is approximately 14.65% of the company’s market cap and around 3.70% of the total institutional ownership; OMEGA FUND MANAGEMENT, LLC, holding 2,602,739 shares of the stock with an approximate value of $14.65 million in PRTK stocks shares; and VANGUARD GROUP INC, currently with $10.17 million in PRTK stock with ownership of nearly 18.372% of the company’s market capitalization.
Positions in Paratek Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 59 institutional holders increased their position in Paratek Pharmaceuticals Inc. [NASDAQ:PRTK] by around 4,151,408 shares. Additionally, 36 investors decreased positions by around 1,590,148 shares, while 16 investors held positions by with 15,825,274 shares. The mentioned changes placed institutional holdings at 21,566,830 shares, according to the latest SEC report filing. PRTK stock had 24 new institutional investments in for a total of 1,308,391 shares, while 10 institutional investors sold positions of 844,715 shares during the same period.